[1] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版). 肝脏,2019,24:1335-1356.
[2] 中国医师协会器官移植医师分会移植免疫学专业委员会, 中国研究型医院学会加速康复外科委员会肝移植加速康复学组. 成人慢加急性肝衰竭肝移植围手术期管理专家共识. 器官移植, 2020, 11: 533-542.
[3] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版). 实用肝脏病杂志, 2019, 22: 164-171.
[4] Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int, 2019, 13: 353-390.
[5] Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology, 2013, 144: 1426-1437, 1437 e1421-1429.
[6] Bajaj JS, O'Leary JG, Reddy KR, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology, 2014, 60: 250-256.
[7] Leao GS, Lunardi FL, Picon RV, et al. Acute-on-chronic liver failure: a comparison of three different diagnostic criteria. Ann Hepatol, 2019, 18: 373-378.
[8] Aday A, O'Leary JG. Acute on chronic liver failure: definition and implications. Clin Liver Dis, 2020, 24: 521-534.
[9] Jindal A, Kumar M, Sarin SK. Management of acute hepatitis B and reactivation of hepatitis B. Liver Int, 2013, 33 Suppl 1: 164-175.
[10] Jindal A, Vyas A, Sharma M, et al. A randomized open label trial of tenofovir monotherapy versus tenofovir plus telbivudine in spontaneous reactivation of hepatitis B. Saudi J Gastroenterol, 2019, 25: 319-326.
[11] Cai Q, Liu W, Zhu M, et al. Microbial infections as a trigger for acute-on-chronic liver failure: a review. Med Sci Monit, 2019, 25: 4773-4783.
[12] Wong F, Piano S, Singh V, et al. Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. J Hepatol, 2020.
[13] 谭立明, 蒙仪妹, 隆婷婷, 等. 降钙素原、D-二聚体、C-反应蛋白对慢加急性肝衰竭患者并发感染的临床意义. 实用医学杂志, 2018, 34: 410-415.
[14] Lin KH, Wang FL, Wu MS, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection in patients with liver cirrhosis: a systematic review and meta-analysis. Diagn Microbiol Infect Dis, 2014, 80: 72-78.
[15] 应高翔, 杨英, 吴凤天, 等. 慢加急性肝衰竭患者并发感染的特点及对诊断的影响. 中华临床感染病杂志, 2020, 13: 140-148.
[16] Verma N, Singh S, Taneja S, et al. Invasive fungal infections amongst patients with acute-on-chronic liver failure at high risk for fungal infections. Liver Int, 2019, 39: 503-513.
[17] 聂青和, 杨洁. 肝衰竭并发侵袭性真菌病的诊治及预防. 临床肝胆病杂志, 2015, 31: 1396-1399.
[18] Wieser A, Li H, Zhang J, et al. Evaluating the best empirical antibiotic therapy in patients with acute-on-chronic liver failure and spontaneous bacterial peritonitis. Digestive and Liver Disease, 2019, 51: 1300-1307.
[19] <Bernsmeier 等。 - 2015 - Immunotherapy in the treatment and prevention of i.pdf>.
[20] Fujiwara K, Yasui S, Yonemitsu Y, et al. Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B. J Gastroenterol, 2008, 43: 711-719.
[21] Gao R, Li Y, Cao Y, et al. Glucocorticoid versus traditional therapy for hepatitis B virus-related acute-on-chronic liver failure: a systematic review and meta-analysis. Medicine (Baltimore), 2020, 99: e20604.
[22] Huang C, Yu KK, Zheng JM, et al. Steroid treatment in patients with acute-on-chronic liver failure precipitated by hepatitis B: a 10-year cohort study in a university hospital in East China. J Dig Dis, 2019, 20: 38-44.
[23] Garg V, Garg H, Khan A, et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology, 2012, 142: 505-512 e501.
[24] Arroyo V, Moreau R, Kamath PS, et al. Acute-on-chronic liver failure in cirrhosis. Nat Rev Dis Primers, 2016, 2: 16041.
[25] Alshamsi F, Alshammari K, Belley-Cote E, et al. Extracorporeal liver support in patients with liver failure: a systematic review and meta-analysis of randomized trials. Intensive Care Med, 2020, 46: 1-16.
[26] Yang Z, Zhang Z, Cheng Q, et al. Plasma perfusion combined with plasma exchange in chronic hepatitis B-related acute-on-chronic liver failure patients. Hepatol Int, 2020, 14: 491-502.
[27] Struecker B, Raschzok N, Sauer IM. Liver support strategies: cutting-edge technologies. Nat Rev Gastroenterol Hepatol, 2014, 11: 166-176.
[28] Garcia Martinez JJ, Bendjelid K. Artificial liver support systems: what is new over the last decade?. Ann Intensive Care, 2018, 8: 109.
[29] Gerth HU, Pohlen M, Tholking G, et al. Molecular adsorbent recirculating system can reduce short-term mortality among patients with acute-on-chronic liver failure-a retrospective analysis. Crit Care Med, 2017, 45: 1616-1624.
[30] Shen Y, Wang XL, Wang B, et al. Survival benefits with artificial liver support system for acute-on-chronic liver failure: a time series-based meta-analysis. Medicine (Baltimore), 2016, 95: e2506.
[31] Jalan R, Gines P, Olson JC, et al. Acute-on chronic liver failure. J Hepatol, 2012, 57: 1336-1348.
[32] Yadav SK, Saraf N, Choudhary NS, et al. Living donor liver transplantation for acute-on-chronic liver failure. Liver Transpl, 2019, 25: 459-468.
[33] 张华鹏, 郭文治, 张水军. 肝癌肝移植治疗. 中华肝脏外科手术学电子杂志, 2019, 8: 473-476.
[34] Sundaram V, Jalan R, Wu T, et al. Factors associated with survival of patients with severe acute-on-chronic liver failure before and after liver transplantation. Gastroenterology, 2019, 156: 1381-1391.e1383.
[35] Sundaram V, Kogachi S, Wong RJ, et al. Effect of the clinical course of acute-on-chronic liver failure prior to liver transplantation on post-transplant survival. J Hepatol, 2020, 72: 481-488.
[36] Ji D, Zhang D, Yang T, et al. Effect of COVID-19 on patients with compensated chronic liver diseases. Hepatol Int, 2020, 14: 701-710.
[37] Zou X, Fang M, Li S, et al. Characteristics of liver function in patients with SARS-CoV-2 and chronic HBV coinfection. Clin Gastroenterol Hepatol, 2020.
[38] Bajaj JS, Garcia-Tsao G, Biggins SW, et al. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut, 2020. |
